Athena Athena

X

Find the latest Drugs in Development and Pipeline Prospector News of Hikma Pharmaceuticals.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Hikma Pharmaceuticals
unitedkingdom_new Flag
Country
Country
United Kingdom
Address
Address
1 New Burlington Place, Mayfair, London, W1S 2HR
Telephone
Telephone
+44 (0) 20 7399 2760

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

Combogesic IV (acetaminophen & ibuprofen) is a opioid-free pain relief medicine. It is approved by USFDA for use in adults for relief of mild to moderate pain & the management of moderate to severe pain as an adjunct to opioid analgesics.


Lead Product(s): Paracetamol,Ibuprofen

Therapeutic Area: Neurology Product Name: Combogesic

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: Hyloris Pharmaceuticals

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 27, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Combogesic IV (acetaminophen & ibuprofen) is a opioid-free pain relief medicine. It is approved by USFDA for use in adults for relief of mild to moderate pain & the management of moderate to severe pain as an adjunct to opioid analgesics.


Lead Product(s): Paracetamol,Ibuprofen

Therapeutic Area: Neurology Product Name: Combogesic

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 05, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the agreement, Hikma gains right for MAb-B43.13 (oregovomab), a murine monoclonal antibody, being tested in combination with carboplatin and paclitaxel for patients with advanced ovarian cancer, in the Middle East and North Africa (MENA) region.


Lead Product(s): Oregovomab,Paclitaxel,Carboplatin

Therapeutic Area: Oncology Product Name: MAb-B43.13

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: CanariaBio

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement October 10, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the terms of the agreement, Hikma will have priority rights for the commercialisation and manufacture of SK Biopharmaceuticals’ current and future pipeline of innovative products for 17 countries in the MENA region.


Lead Product(s): Cenobamate

Therapeutic Area: Neurology Product Name: Xcopri

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: SK Biopharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement August 21, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the terms of the agreement, Hikma has an exclusive license to commercialize products in Rakuten Medical's pipeline using its photoimmunotherapy technology platform, Alluminox™, in all its MENA markets.


Lead Product(s): Cetuximab Sarotalocan Sodium

Therapeutic Area: Oncology Product Name: ASP-1929

Highest Development Status: Phase IIIProduct Type: Large molecule

Recipient: Rakuten Medical

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement August 10, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Dobutamine injection stimulates heart muscle and improves blood flow by helping the heart pump better, which is used short-term to treat cardiac decompensation due to weakened heart muscle.


Lead Product(s): Dobutamine Hydrochloride

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Dobutamine-Generic

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 14, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Tuoyi (toripalimab) is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function).


Lead Product(s): Toripalimab

Therapeutic Area: Oncology Product Name: Tuoyi

Highest Development Status: ApprovedProduct Type: Large molecule

Recipient: Shanghai Junshi Biosciences

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement December 26, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The efficacy and safety of RYALTRIS (olopatadine hydrochloride) was established in a robust clinical studies program in over 4,000 patients with SAR. Twice-daily RYALTRIS™ provided statistically significant improvement in both nasal and ocular symptoms vs placebo.


Lead Product(s): Olopatadine Hydrochloride,Mometasone Furoate

Therapeutic Area: Immunology Product Name: Ryaltris

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 30, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The combination with Custopharm enhances Hikma’s R&D capabilities and pipeline and expands Hikma’s differentiated US portfolio to close to 130 commercialised injectable medicines – a more than fivefold increase over the last decade, including Acetaminophen injection.


Lead Product(s): Paracetamol

Therapeutic Area: Neurology Product Name: Acetaminophen-Generic

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: Custopharm

Deal Size: $425.0 million Upfront Cash: $375.0 million

Deal Type: Acquisition April 21, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The acquisition marks Hikma’s expansion into Canada and a portfolio of 25 sterile injectable products including the marketed product Atropine-G, three in-licenced ophthalmic products and a pipeline of seven additional products, four of which are approved by Health Canada.


Lead Product(s): Atropine

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Atropine-Generic

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: Teligent, Inc

Deal Size: $45.8 million Upfront Cash: Undisclosed

Deal Type: Acquisition January 17, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY